-
Ionetix Begins Shipping Astatine-211 to Support Preclinical and Clinical Trials
A manufacturer of proprietary superconducting cyclotrons and producer of medical isotopes for diagnostic imaging and targeted alpha therapy, today announced it has begun routine shipment of astatine-211 (At-211)
-
Ionetix Announces Approval of Abbreviated New Drug Application for Gallium Ga-68 Gozetotide (PSMA-11)
Ionetix receives FDA ANDA approval for Gallium Ga-68 gozetotide, becoming the first commercial manufacturer approved for this PSMA-PET imaging agent.
-
Ionetix Completes $30 million+ Financing in a Go-Public Transaction
Ionetix Corporation (“Ionetix”), a leading particle accelerator company focused on the medical, materials testing and nuclear energy space announced today it raised more than $30 million in a private placement offering at $3.00 per share.
-
Ionetix Invests $25.75M in Delta Township Facility, Creating 53 High-Tech Jobs and Advancing Lansing’s MedTech Leadership
Ionetix invests $25.75M in Delta Township, creating 53 high-tech jobs and enhancing Michigan's leadership in MedTech and cancer treatment innovations.
-
Ionetix Launches Commercial Actinium-225 Production | Ac-225
Ionetix achieves first commercial-scale Actinium-225 (Ac-225) production using proprietary cyclotron technology at its new alpha-emitting isotope facility in Lansing, MI.
-
Ionetix announces appointment of Douglas Boothe to Board of Directors
Ionetix, a leading cyclotron technology and isotope manufacturing company, is pleased to announce the appointment of Douglas Boothe to its Board of Directors.